4/A: ALX Oncology CFO Peter Garcia Amends Form 4 After Short-Swing Profit Recovery

ALX Oncology's CFO, Peter Garcia, files an amended Form 4 disclosing a purchase of 12,000 shares and a subsequent agreement to reimburse the company for profits from a short-swing transaction.

Summary

• Peter Garcia, CFO of ALX Oncology Holdings Inc., filed an amendment to his Form 4 on June 24, 2024, regarding transactions in ALX Oncology's common stock.
• The original filing date was June 17, 2024.
• On June 13, 2024, Garcia purchased 12,000 shares of common stock at a weighted average price of $8.5282 per share.
• The purchase price ranged from $8.4113 to $8.68 per share.
• Following the reported transaction, Garcia beneficially owns 122,348 shares of ALX Oncology common stock directly.
• The filing addresses a potential short-swing profit recovery issue related to a sale of 1,893 shares on December 29, 2023, to cover tax obligations from vesting restricted stock units.
• Garcia has agreed to pay ALX Oncology $11,959.88, representing the profit from the short-swing transaction, less transaction costs.

Sentiment

Score: 5

Explanation: Neutral sentiment as it primarily reports a transaction and a subsequent correction. The short-swing profit issue is a minor negative, but the resolution is a positive.

Positives

• Garcia's purchase of 12,000 shares demonstrates confidence in ALX Oncology.
• The agreement to reimburse the company for the short-swing profit resolves a potential legal issue.

Negatives

• The short-swing profit issue indicates a potential oversight in compliance with Section 16(b) of the Securities Exchange Act of 1934.

Risks

• Potential for future scrutiny regarding compliance with insider trading regulations.
• Reputational risk associated with the short-swing profit recovery.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. The short-swing profit rule is designed to prevent insiders from using non-public information for quick profits.

Comparison to Industry Standards

• Short-swing profit recoveries are not uncommon, but they can raise concerns about internal controls and compliance.
• Companies like Regeneron and Amgen also have similar insider trading policies and reporting requirements.

Stakeholder Impact

• Shareholders may be concerned about the short-swing profit issue, but the resolution should reassure them.
• Employees may need additional training on insider trading policies.

Key Dates